Stay updated on the latest advancements in bladder cancer treatment and the financial decisions of a leading company in the ...

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

- This is Dermata's first allowed U.S. patent application for DMT310, using its Spongilla technology to topically treat acne - - Dermata recently completed enrollment in its DMT310 Phase 3 STAR-1 ...

The ocean's biodiversity is a key source of marine-derived compounds, fueling pharmaceutical innovations and drug discovery ...

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

With a growing portfolio in an attractive rare-disease niche—and acceleration of profit growth beginning in 2022—BioMarin could be an acquisition target for pharmaceutical firms with pipelines to fill ...

The FDA has issued a Complete Response Letter regarding the NDA for govorestat for the treatment of classic galactosemia.

If you are an Applied Therapeutics investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.

Capricor Therapeutics raised $86.3 million in a public offering, ensuring sufficient cash runway to fund operations into 2027 ...

President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such ...

Applied Therapeutics’ CEO Shoshana Shendelman has a debilitating credibility problem: She repeatedly misled investors prior ...